A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer

By Ko Andrew   Venook Alan   Bergsland Emily   Kelley R.   Korn W.   Dito Elizabeth   Schillinger Brian   Scott Janet   Hwang Jimmy   Tempero Margaret  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1051-1057

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere

By Soares Heloisa   Bayraktar Soley   Blaya Marcelo   Lopes Gilberto   Merchan Jaime   Macintyre Jessica   Mayo Carlos   Green Mark   Silva Orlando   Levi Joe   Walker Gail   Rocha-Lima Caio  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 839-845

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer

By Hirose Takashi   Shirai Takao   Ishida Hiroo   Ando Kohichi   Sugiyama Tomohide   Kusumoto Sojiro   Hosaka Takamichi   Nakashima Masanao   Ohmori Tohru   Adachi Mitsuru  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 267-274

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer

By Ueno Hideki   Okusaka Takuji   Funakoshi Akihiro   Ishii Hiroshi   Yamao Kenji   Ishikawa Osamu   Ohkawa Shinichi   Saitoh Soh  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 447-454

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabinerefractory pancreatic cancer patients

By                                  

Oncology Letters, Vol. 3, Iss. 6, 2012-01 ,pp. : 1314-1318

Spandidos Publications

Access to resources Recommend Favorite